A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.

被引：0
|
作者：
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Mazumder, Amitabha
Chamoun, Kamal
Karasik, Igor
Sbar, Eric
Dugon, Laura
Tamir, Sharon
Wang, Xulong
Prchal, Josef T.
Tantravahi, Srinivas Kiran
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Mt Sinai St Lukes Roosevelt Hosp, New York, NY USA
[3] VCU Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ Sch Med, Nashville, TN USA
[5] Oncol Inst Hope Innovat, Tampa, FL USA
[6] Karyopharm Therapeutics Inc, Newton, MA USA
[7] Karyopharm Therapeut, Newton, MA USA
[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[9] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7060
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S389 - S389
  • [42] Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
    Hong, D. S.
    Bauer, T. M.
    Lee, J. J.
    Dowlati, A.
    Brose, M. S.
    Farago, A. F.
    Taylor, M.
    Shaw, A. T.
    Montez, S.
    Meric-Bernstam, F.
    Smith, S.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Cox, M. C.
    Burris, H. A., III
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 325 - 331
  • [43] Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
    Alexander, Thomas
    Khaw, Seong Lin
    Rubnitz, Jeffrey E.
    Vear, Susan I.
    Lacayo, Norman James
    Schmidt, Michelle
    Tong, Bo
    Rosenwinkel, Lindsey
    Bensman, Lindsey
    Verdugo, Maria
    Kim, Su Young
    Jabbour, Elias
    Stock, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
    Imamura, Keiko
    Izumi, Yuishin
    Nagai, Makiko
    Nishiyama, Kazutoshi
    Watanabe, Yasuhiro
    Hanajima, Ritsuko
    Egawa, Naohiro
    Ayaki, Takashi
    Oki, Ryosuke
    Fujita, Koji
    Uozumi, Ryuji
    Morinaga, Akiko
    Hirohashi, Tomoko
    Fujii, Yosuke
    Yamamoto, Takuya
    Tatebe, Harutsugu
    Tokuda, Takahiko
    Takahashi, Naoto
    Morita, Satoshi
    Takahashi, Ryosuke
    Inoue, Haruhisa
    ECLINICALMEDICINE, 2022, 53
  • [45] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    Amorim, Sandy
    Stathis, Anastasios
    Gleeson, Mary
    Iyengar, Sunil
    Magarotto, Valeria
    Leleu, Xavier
    Morschhauser, Franck
    Karlin, Lionel
    Broussais, Florence
    Rezai, Keyvan
    Herait, Patrice
    Kahatt, Carmen
    Lokiec, Francois
    Salles, Gilles
    Facon, Thierry
    Palumbo, Antonio
    Cunningham, David
    Zucca, Emanuele
    Thieblemont, Catherine
    LANCET HAEMATOLOGY, 2016, 3 (04): : E196 - E204
  • [46] Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial
    Naik, Haley B.
    Pichard, Dominique C.
    Schwartz, Daniella M.
    O'Brien, Michelle
    Masciocchi, Matthew
    Thompson, Julie
    Sen, H. Nida
    Steinberg, Seth M.
    Mitchell, Sandra A.
    de Jesus, Adriana A.
    McCalmont, Timothy H.
    Dey, Amit
    Rosenstein, Rachel K.
    Deng, Zuoming
    Goldbach-Mansky, Raphaela
    Mehta, Nehal N.
    Cowen, Edward W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1380 - 1383
  • [47] A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naive patients with chronic hepatitis B
    Yuen, Man-Fung
    Chen, Chi-Yi
    Liu, Chun-Jen
    Jeng, Wen-Juei
    Elkhashab, Magdy
    Coffin, Carla S.
    Kim, Won
    Greenbloom, Susan
    Ramji, Alnoor
    Lim, Young S.
    Kim, Yoon J.
    Fung, Scott K.
    Kim, Dong J.
    Jang, Jeong-Won
    Lee, Kwan Sik
    Iyer, Radhakrishnan P.
    Macfarlane, Chelsea
    Jackson, Kathy
    Locarnini, Stephen A.
    Chan, Henry L. Y.
    Afdhal, Nezam H.
    LIVER INTERNATIONAL, 2023, 43 (01) : 77 - 89
  • [48] Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naive Myelofibrosis.
    Yacoub, Abdulraheem
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    CANCER RESEARCH, 2021, 81 (13)
  • [50] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Chris Twelves
    Alan Anthoney
    Claudio I. Savulsky
    Matthew Guo
    Larisa Reyderman
    Nicola Cresti
    Vladimir Semiglazov
    Constanta Timcheva
    Ishtiaq Zubairi
    Rosemary Morrison
    Ruth Plummer
    T. R. Jeffry Evans
    British Journal of Cancer, 2019, 120 : 579 - 586
12345